Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

BMC Medicine (Impact Factor: 7.28). 01/2013; 11(1):17. DOI: 10.1186/1741-7015-11-17
Source: PubMed

ABSTRACT Methotrexate (MTX) is the central drug in the management of rheumatoid arthritis (RA) and other immune mediated inflammatory diseases. It is widely used either in monotherapy or in association with other synthetic and biologic disease modifying anti-rheumatic drugs (DMARDs). Although comprehensive clinical experience exists for MTX and synthetic DMARDs, to date it has not been possible to preview correctly whether or not a patient will respond to treatment with these drugs. Predicting response to MTX and other DMARDs would allow the selection of patients based on their likelihood of response, thus enabling individualized therapy and avoiding unnecessary adverse effects and elevated costs. However, studies analyzing this issue have struggled to obtain consistent, replicable results and no factor has yet been recognized to individually distinguish responders from nonresponders at treatment start. Variables possibly influencing drug effectiveness may be disease-, patient- or treatment-related, clinical or biological (genetic and nongenetic). In this review we summarize current evidence on predictors of response to MTX and other synthetic DMARDs, discuss possible causes for the heterogeneity observed and address its translation into daily clinical practice.

Download full-text


Available from: João Fonseca, Mar 29, 2014
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Although methotrexate (MTX) is the most used drug in rheumatoid arthritis (RA) treatment, variability in clinical response is often observed, with genetic polymorphisms to be referred as important. We aimed to elucidate the role of methylenetetrahydrofolate reductase (MTHFR) C677T and aminoimidazole carboxamide adenosine ribonucleotide transformylase (ATIC) T675C polymorphisms and clinicopathological variables in clinical response to MTX in Portuguese RA patients. Methods: Study included 233 RA patients treated with MTX for at least six months. Non-response was defined as a Disease Activity Score in 28 joints (DAS28) >3.2 in two consecutive evaluations. MTHFR C677T and ATIC T675C polymorphisms were genotyped and clinicopathological variables collected from all patients. Statistical analyses were performed and binary logistic regression method adjusted to possible confounding variables. Results: Multivariate analyses demonstrated that MTHFR 677TT (OR=4.63; P=0.013) and ATIC 675T carriers (OR=5.16; P=0.013) were associated with over 4-fold increased risk for non-response. Additionally, and considering clinicopathological variables, we observed that non-current smokers (OR=7.98; P=0.001), positivity to anti-cyclic citrullinated peptide (OR=3.53; P=0.004) and to antinuclear antibodies (OR=2.28; P=0.045), higher health assessment questionnaire score (OR=2.42; P=0.007) and non-steroidal anti-inflammatory drugs users (OR=2.77; P=0.018) were also associated with non-response. Contrarily, subcutaneous administration route (OR=0.11; P<0.001) was associated with response to MTX. Conclusion: Our study suggests that MTHFR C677T and ATIC T675C genotyping combined with clinicopathological data may help to identify patients whom will not benefit from MTX treatment and, therefore, assist clinicians to personalize RA treatment.
    BioMed Research International 05/2014; 2014(Article ID 368681):11 pages, 2014. DOI:10.1155/2014/368681 · 2.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To measure circulating anti-citrullinated peptide antibodies (ACPA) and cytokines pre- and 6 months post-therapy as a strategy to predict and optimize responses to traditional disease-modifying antirheumatic drugs (DMARDs) in early RA, which is an unmet need in developing countries. A cohort of 140 predominantly (88.5 %) black female South African patients with early RA was treated with synthetic DMARDs, mostly methotrexate (MTX) alone, or in combination with low-dose oral corticosteroids (CS). Circulating ACPA and a panel of circulating cytokines/chemokines/growth factors were measured at baseline and after 6 months of therapy in relation to disease activity and Shared Epitope (SE). Following 6 months of therapy, the median simplified disease activity index (SDAI) declined from a baseline of 41.4 to 16.0 (p = 0.0001) for the entire cohort, which was paralleled by significant falls in median serum ACPA levels (516.6 vs. 255.7 units/ml, p = <0.0001) and several of the circulating cytokines (IL-4, IL-7, IL-8, G-CSF, VEGF; p < 0.0010 - p < 0.0001) which were most evident in the subgroup of patients treated with a combination of MTX and CS. Although biomarker concentrations decreased most notably in the low-disease activity group post-therapy, no significant correlations between these biomarkers and disease activity were observed, Baseline ACPA levels, but not SDAI or cytokines, were significantly higher in the subgroup of risk allele-positive patients (561.1 vs. 331.9 units/ml, p < 0.05), while no associations with ACPA and a smoking history were evident. The use of DMARDs in RA is associated with significant decreases in ACPA and cytokines which did not correlate with changes in SDAI, precluding the utility of serial measurement of these biomarkers to monitor early responses to therapy, but may have prognostic value.
    BMC Musculoskeletal Disorders 05/2015; 16(1). DOI:10.1186/s12891-015-0587-1 · 1.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: KIR genes coding for natural killer cell immunoglobulin-like receptors, KIR, influence the effector and regulatory function of NK cells as well as some subpopulations of T lymphocytes (e.g. CD4 + CD28-KIR+) depending on presence of ligands (particularly HLA-C molecules). KIR-KIR ligand interaction may lead to the development of autoimmune disorders, including rheumatoid arthritis (RA). However, their role in the response of RA patients to methotrexate therapy is not known.
    BMC Musculoskeletal Disorders 07/2014; 15(1):256. DOI:10.1186/1471-2474-15-256 · 1.90 Impact Factor